Although Lucid Diagnostics Inc (NASDAQ:LUCD) reported a revenue miss in its first-quarter print, its top-line is expected to grow "significantly" in 2026 and 2027, according to Ascendiant Capital analyst Edward Woo.
The Lucid Diagnostics Analyst: Woo maintained a Buy rating, and raised the price target from $9.00 to $9.25.
The Lucid Diagnostics Thesis: There is "significant upside from the current share price," Woo wrote regarding the medical technology company.
Check out other analyst stock ratings.
He noted the highlights of Lucid Diagnostics' first-quarter print: Revenue of $1.3 million missed consensus estimates of $1.4 million Pro forma net loss of $10.5 million equates to a loss of 7 cents per share, better than consensus of a loss of 8 cents per share Operating expenses declined to $12 million, from $14 million in the previous quarter The company processed 3,177 EsoGuard tests (esophageal DNA tests) in the first quarter, representing a decline from 3,664 tests in the previous quarter, but higher than 3,034 tests in the first quarter of 2025.
